We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Use of interferon-β in the treatment of multiple sclerosis].
Nihon Rinsho. Japanese Journal of Clinical Medicine 2014 November
Interferon-β (IFNβ) products are widely used as first-line treatment for multiple sclerosis and have well-established benefit-risk profiles over the short- and long-term. Commercially available agents in Japan include subcutaneous IFNβ-1β (Betaferon) and intramuscular IFNβ-1a(Avonex). Although these IFNβ products differ in dosage, frequency of administration and rout of delivery, both reduce relapse rate by about 30% and new lesion activity by about 65%. In addition, IFNβ products were shown to reduce the disability progression. However, clinical studies have also demonstrated that a subset of patients respond poorly to IFNβ treatment. Thus, it is an important strategy to identify the patients who have suboptimal treatment responses early, before disability ensures, as measured by combination of clinical data and MRI measures of disease activity.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app